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STATE-OF-THE-ART REVIEW
Emerging Therapeutics for the
Treatment of Light Chain and
Transthyretin Amyloidosis
Kathleen W. Zhang, MD,a Keith E. Stockerl-Goldstein, MD,b Daniel J. Lenihan, MDa
HIGHLIGHTS
 Cardiac amyloidosis has high associated morbidity and, until recently, limited treatment options.
 This review discusses the mechanism and clinical trial performance of multiple emerging therapies.
 Additional studies should identify optimal treatment paradigms and biomarker strategies for cardiac response to therapy.
SUMMARY
Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or
transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and
transthyretin (ATTR) amyloidosis have been limited. However, there are now multiple novel therapeutics in development
and several therapeutics recently approved that promise to revolutionize clinical management of AL and ATTR. Most of
these agents disrupt speciﬁc stages of amyloidogenesis such as light chain or transthyretin protein production, formation
of amyloidogenic intermediates, or amyloid ﬁbril aggregation. Others aim to remove existing amyloid tissue deposits
using monoclonal antibody technology. Although these advances represent an important step forward in the care of
cardiac amyloidosis patients, additional studies are needed to deﬁne the optimal treatment paradigms for AL and
ATTR and to validate clinical, imaging, or serum biomarker strategies that may conﬁrm a cardiac response to therapy.
(J Am Coll Cardiol Basic Trans Science 2019;4:438–48) © 2019 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
C ardiac amyloidosis is a restrictive cardiomy-opathy that results from the deposition ofamyloid ﬁbrils in cardiac tissue, causing
progressive heart failure (HF) with median survival
of 2 to 4 years (1,2). Two types of amyloid protein
cause more than 95% of cardiac amyloidosis: immu-
noglobulin light chain, which causes light chain
amyloidosis (AL), and transthyretin, which causes he-
reditary or wild-type (previously called senile sys-
temic amyloidosis) transthyretin amyloidosis (ATTR).
Although hereditary ATTR (3) and AL (4) are
uncommon conditions, wild-type ATTR is likely
underdiagnosed particularly among patients with HF
with preserved ejection fraction (EF) and calciﬁc
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aortic stenosis (5–9). Despite growing clinical recog-
nition of the disease, availability of reliable nonin-
vasive diagnostic techniques (10), and signiﬁcant
associated morbidity and mortality, pharmacologic
agents have yet to receive regulatory approval spe-
ciﬁcally for AL or ATTR with cardiac involvement.
This review highlights the new and emerging
therapies for AL and ATTR with emphasis on their
mechanistic effects on the amyloid disease-producing
process and performance in early clinical trials. It is
apparent that additional studies are needed to deﬁne
the optimal treatment paradigms and to measure
therapeutic cardiac response in light chain (AL-CA)
and transthyretin (ATTR-CA) cardiac amyloidosis.
LIGHT CHAIN AMYLOIDOSIS
BACKGROUND. AL results from the extracellular
deposition of amyloid ﬁbrils composed of monoclonal
immunoglobulin light chains, which are produced by
an underlying clonal plasma cell proliferative disorder
such as multiple myeloma (MM) (Central Illustration,
panel A). Ten percent to 15% of patients with MM
develop AL; however, the majority of AL patients
have <10% plasma cells in the bone marrow (11).
Monoclonal gammopathy of undetermined signiﬁ-
cance (MGUS) is a known precursor of both MM and
AL, and progresses to AL in 1.0% of cases with a
relative risk of 8.8 as compared to the general popu-
lation (12). The light chain amyloid ﬁbrils in AL derive
mostly from N-terminal amino acid residues of light
chain immunoglobulin variable regions, and arise
more commonly from l light chains than k (11).
The exact mechanism of AL pathogenesis and the
resultant pathophysiological changes that lead from
MGUS or MM to AL are currently unknown. The
monoclonal plasma cells in AL share many genetic
abnormalities with the plasma cells in MM and MGUS,
namely, gain of chromosomes 7, 9, 11, 15, and 18, loss
of chromosome 18 (13), translocation of the immu-
noglobulin heavy chain gene at 14q32 (14,15), and
deletion of the long arm of chromosome 13 [del(13q)]
(16). However, functional gene expression analyses
show a unique molecular proﬁle for AL as compared
with MM including higher expression of CD27 SDF-1
(17). AL clonal plasma cells also show a number of
deregulated genes and pathways involving protein
processing and folding.
Current standard-of-care for newly diagnosed AL is
based on antimyeloma therapy and consists of
autologous stem cell transplantation (ASCT) for
eligible patients or bortezomib-based chemotherapy
for high-risk patients who are transplant-ineligible.
Five-year survival with upfront bortezomib-based
regimens lags behind that with upfront
ASCT (55% versus 84%) (18,19), although the
2 strategies have not been compared in a
clinical trial setting and the transplant-
ineligible population is generally sicker with
more comorbidities. Additionally, up to 45%
of patients have progression of cardiac dis-
ease despite complete hematologic response
with initial therapy (20), possibly related to
obstructive intramural coronary amyloidosis,
subendocardial ischemia, and/or interstitial
ﬁbrosis (21,22). There remains a critical need
for novel therapeutic agents that improve
cardiac response to AL therapy.
PROTEASOME INHIBITORS. Protein degra-
dation is an essential cellular function carried
out by the proteasome. Proteasome inhibition
causes cell cycle arrest and cellular apoptosis,
with proliferating malignant cells showing
higher susceptibility than normal cells (23). Bortezo-
mib is a boronic acid dipeptide that inhibits the 20S
proteasome by binding to the catalytic b subunits
lining the inner ring of the 20S core particle in a
reversible manner (23,24).
Ixazomib is a second-generation boronic acid
dipeptide proteasome inhibitor that binds reversibly
to the 20S proteasome. Because of a shorter protea-
some dissociation half-life, ixazomib has signiﬁcantly
larger volume of distribution and greater tumor pro-
teasome inhibition than bortezomib in vivo, allowing
for higher doses of administration and greater plasma
exposure (24). Compared to lenalidomide and dexa-
methasone alone, addition of ixazomib reduced dis-
ease progression or death in patients with relapsed/
refractory MM with a hazard ratio (HR) of 0.74 (25).
No excess of adverse events was seen with ixazomib.
A phase I/II trial of ixazomib in 27 patients with
relapsed/refractory AL showed encouraging hemato-
logic (52%) and organ (56%) response rates with only
3 patients experiencing dose-limiting toxicity
(NCT01318902) (26). A phase III trial of ixazomib in the
AL population is ongoing (NCT01659658) (Table 1).
Carﬁlzomib is a modiﬁed epoxyketone that binds
the 20S proteasome irreversibly and with higher
selectivity than bortezomib. As compared with lena-
lidomide and dexamethasone alone, the addition of
carﬁlzomib in relapsed MM improved 24-month sur-
vival by 21% and also led to signiﬁcant improvement
in hematologic response rate (27). Cardiovascular
toxicities (hypertension, cardiac failure, and ischemic
heart disease) were among the major adverse effects.
In a phase I/II trial of carﬁlzomib monotherapy in 28
patients with previously treated AL, 63% showed
AB BR E V I A T I O N S
AND ACRONYM S
AL = light chain amyloidosis
ATTR = transthyretin
amyloidosis
ASCT = autologous stem cell
transplantation
CA = cardiac amyloidosis











SAP = serum amyloid P
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hematologic response although pulmonary, renal,
and cardiac toxicities were common (28) (NCT01789242).
Because of advanced cardiac disease in many AL
patients, the role of carﬁlzomib in standard AL
treatment paradigms remains to be determined.
IMMUNOMODULATORY AGENTS. The immunomod-
ulatory agents (IMiDs) include thalidomide and its
analogues, and have therapeutic efﬁcacy in a wide
range of malignancies. Recent studies have shown
that the IMiDs exert antimyeloma activity by acti-
vating the E3 ubiquitin ligase activity of the protein
cereblon. Binding of the IMiDs to cereblon results in
the rapid ubiquitination and degradation of Ikaros
(IKZF1) and Aiolos (IKZF3), 2 key transcriptional reg-
ulators of B and T cell development (29). Lenalido-
mide is a second-generation synthetic thalidomide
that has been in use for AL. In 69 patients with AL
treated with lenalidomide and dexamethasone, 16%
of patients achieved a complete response (CR) in an
intent-to-treat analysis (NCT00091260) (30). The
median time to achieve a CR was 6 months with 60%
of CRs considered durable.
Pomalidomide is a newer thalidomide analogue
with more potent antimyeloma activity than lenali-
domide. As with lenalidomide, it inhibits pro-
inﬂammatory cytokine production and angiogenesis,
induces apoptosis and cell cycle arrest, and activates
T cells and natural killer cells (31). A phase I trial of
pomalidomide and dexamethasone in 33 patients
with previously treated AL showed hematologic
response rate of 48% and organ response rate of 15%
(32) (NCT01807286). Twenty-seven patients (82%)
had cardiac involvement but only 4 showed cardiac
response. This trial was terminated early during the
phase I portion without continuation to phase II.
Trials using the IMiDs thalidomide, lenalidomide,
and pomalidomide have repeatedly shown that pa-
tients with AL have a poor tolerance for these agents
when used at the standard doses typically prescribed
for MM, although it is unclear why this occurs (33).
The precise role and optimal sequence of the IMiDs in
the treatment of AL remains unclear.
MONOCLONAL ANTIBODIES. CD38 and SLAMF7
(also known as CD319 and CS1) are cell surface anti-
gens speciﬁc to MM cells that are being evaluated as
targets of monoclonal antibody (mAb) therapeutics in
MM and AL.
CD38 is a type II transmembrane glycoprotein that
associates with cell-surface receptors in lipid rafts,
regulates cytoplasmic Ca2þ ﬂux, and mediates signal
transduction in lymphoid and myeloid cells (34). It
is expressed at low level on normal lymphoid
and myeloid cells and in some tissues of non-
hematopoietic origin, but it is highly and uniformly
expressed on plasma cells in patients with MM and AL
(35,36). Daratumumab is a human immunoglobulin
(Ig) G1k mAb that targets the extracellular domain of
CD38 (37). In vitro, daratumumab kills MM cells by
antibody-dependent cellular cytotoxicity and
complement-dependent cytotoxicity, and is highly
efﬁcacious in both early- and late-treatment settings
in in vivo tumor models (37). Two large phase III trials
showed improved progression-free survival (PFS)
with daratumumab in combination with either lena-
lidomide and dexamethasone or bortezomib and
dexamethasone in patients with relapsed/refractory
MM (38,39). A retrospective analysis of 25 patients
with refractory AL who received daratumumab and
dexamethasone showed overall hematologic
response rate of 76% including CR in 36% (40).
Therapy was well tolerated without any grade 3 or 4
reactions observed, even among the 72% of patients
with cardiac involvement. A phase III trial of dar-
atumumab, cyclophosphamide, bortezomib, and
dexamethasone in patients with newly diagnosed AL
is ongoing (NCT03201965).
Isatuximab is a chimeric IgG1 monoclonal antibody
that targets CD38 as an allosteric antagonist (41).
In vivo, isatuximab showed antitumor activity in
multiple cancer models including MM, lymphoma,
and leukemia. In a phase Ib trial of isatuximab,
lenalidomide, and dexamethasone for relapsed/re-
fractory multiple myeloma, the overall hematologic
response rate was 56% and median PFS was
8.5 months, indicative of clinical beneﬁt without
signiﬁcant toxicity (42). A phase II trial of isatuximab
in patients with relapsed/refractory AL is ongoing
(NCT03499808).
SLAMF7 is a member of the Signaling Lymphocyte
Activation Molecule Family and is expressed at low
level on natural killer cells, CD8þ T cells, B cells, and
mature dendritic cells (43). Normal plasma cells and
MM cells express high levels of SLAMF7 mRNA and
protein (44), and targeting of SLAMF7 using mAbs led
to antibody-dependent cellular cytotoxicity and
reduction in myeloma activity in vivo. Although the
mechanism of SLAMF7 upregulation in MM is un-
known, small interfering RNA inhibition of SLAMF7
expression inhibited MM cell adhesion to bone
marrow stromal cells (45). Elotuzumab is a human-
ized recombinant IgG1k mAb that targets the extra-
cellular region of SLAMF7 (44). In patients with
relapsed/refractory MM, the addition of elotuzumab
to lenalidomide and dexamethasone improved me-
dian PFS from 14.9 to 19.4 months, with overall
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response rate (ORR) of 79% (improved from 66%)
(46). Elotuzumab gained U.S. Food and Drug Admin-
istration approval for relapsed/refractory MM in 2015,
and is currently in a phase II trial for patients with
relapsed AL (NCT03252600).
SMALL MOLECULE INHIBITORS. Modulation of
intrinsic apoptotic pathways offers an additional
mechanism by which to treat AL amyloidosis. BCL-2 is
a central regulator of programmed cell death that
binds and sequesters pro-apoptotic proteins (47).
Elevated expression of anti-apoptotic proteins is
common in MM and associated with resistance to
therapy (48). Venetoclax is a small molecule that
binds with high afﬁnity to the binding pocket on BCL-
2 speciﬁc for the BH3 region of intrinsic pro-apoptotic
proteins (47). In vitro, venetoclax inhibits interaction
of BCL-2 with pro-apoptotic proteins within the
mitochondria, and induces apoptosis in lymphoma
and leukemia cells as well as tumor regression in
in vivo solid tumor models (47). In human myeloma
cell lines and primary MM samples, sensitivity to
venetoclax was highest in the presence of the (11;14)
translocation, which correlated with higher ratios of
BCL2 and MCL1 mRNA (49). t(11;14) is seen in 15% to
20% of patients with MM, and may be a marker of
intermediate-risk disease (50).
A phase I trial of venetoclax monotherapy in 66
patients with relapsed/refractory MM showed an ORR
of 21%; among patients with t(11;14), the ORR was
doubled at 40% (51). Similarly, time to progression of
disease was 6.6 months in patients with t(11;14) and
1.9 months in those without t(11;14). There were no
adverse cardiac events, and changes in cardiac pa-
rameters with therapy were not evaluated. A separate
phase Ib trial of venetoclax in combination with bor-
tezomib and dexamethasone showed better ORR at
67%, with time to progression of 9.7 months (52).
Again, patients with higher BCL2 expression had a
higher ORR (94%) as compared to patients with low
BCL2 expression (59%). A phase I trial of venetoclax
and dexamethasone in patients with relapsed/
refractory AL is ongoing (NCT03000660).
DOXYCYCLINE. Matrix metalloproteinases (MMPs)
and their tissue inhibitors are key regulators of car-
diac extracellular matrix homeostasis, which is dis-
rupted by amyloid inﬁltration resulting in thickening
and stiffening of the myocardium. Elevation in MMP
and tissue inhibitor of matrix metalloproteinase
serum levels and tissue expression have been asso-
ciated with renal and cardiac damage in AL (53,54),
suggesting that inhibition of the MMP pathway may
mitigate the cardiotoxic effects of light chain amyloid
ﬁbril deposition. Doxycycline is a semisynthetic
tetracycline antibiotic that inhibits bacterial protein
synthesis and, separately, also acts as an inhibitor of
MMPs. Doxycycline inhibits the formation of light
chain amyloid ﬁbrils in vivo and ex vivo in a dose-
dependent manner, and prevented light chain amy-
loid deposition in a mouse model of AL (55). In a
retrospective cohort study of 103 patients with AL-
CA, 24-month survival improved from 40% to 82%
by administering doxycycline along with chemo-
therapy whereas cardiac response to therapy
improved 3-fold to 60% (56). Multiple clinical trials
of doxycycline in conjunction with plasma cell-
directed therapy in patients with AL are ongoing
(NCT02207556, NCT03474458, and NCT03401372).
CLEARANCE OF AMYLOID DEPOSITS. Mouse models
of human AL amyloidomas showed spontaneous tu-
mor regression in association with neutrophil inﬁl-
tration and production of antibodies targeted to k and
l light chain extracts (57), suggesting that exogenous
administration of anti-amyloid antibodies may expe-
dite clearance of amyloid deposits.
11-1F4 (CAEL-101) is a chimeric monoclonal IgG1
antibody that targets the VL fragment of human
K Bence Jones protein, with stronger afﬁnity for k light
chain than l (57,58). 11-1F4 interacts immunohis-
tochemically with human AL deposits in hepatocytes,
proximal renal tubules, and myocytes, and facilitates
regression of AL amyloidomas in vivo (58). In a phase
Ia/b dose-escalation study in 27 patients with
relapsed/refractory AL, 62% of patients showed organ
response at a median of 2 weeks after starting treat-
ment (NCT02245867) (59). In patients with cardiac
involvement, 11-1F4 led to a statistically signiﬁcant
improvement in global longitudinal strain (GLS) after
12 weeks of follow-up (60). A randomized phase II/III
trial for newly diagnosed AL patients is planned, in-
clusive of a high-risk patient cohort with N-terminal
prohormone of brain natriuretic peptide (NT-proBNP)
> 8,500 ng/L. Additionally, a radiolabeled peptide
comprising a 11-1F4 epitope and a pan-amyloid-
reactive peptide is in development which may
enable the use of 11-1F4 as a diagnostic imaging agent
for AL and other forms of amyloidosis (61).
NEOD001 is a humanized mAb originally devel-
oped for secondary amyloidosis but found to target
AL deposits with high afﬁnity. It targets the
C-terminal amino acid sequence of murine serum
amyloid A protein, which is exposed during the
process of AA amyloid deposition and is not acces-
sible in the full-length serum amyloid A molecule
(62). NEOD001 binds AL amyloid deposits in situ,
induces phagocytic clearance of AL deposits, and
expedites clearance of AL amyloidomas (63,64).
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NEOD001 performed well in a phase I/II trial of pa-
tients with AL and persistent organ dysfunction af-
ter therapy (65). However, a phase II trial failed to
meet its primary endpoint of cardiac response as
measured by NT-proBNP (NCT02632786), and a
subsequent phase III trial was discontinued prema-
turely for futility (NCT02312206) (66). Failure of
these late-phase clinical trials may have stemmed
from issues with study design, such as the use of
biomarker-based endpoints in NCT02632786 and a
composite clinical endpoint in NCT02312206 as
opposed to best response analysis. Further
development of NEOD001 for AL was halted in
April 2018.
CENTRAL ILLUSTRATION Pathophysiology of Light Chain and Transthyretin Amyloidosis and
Mechanism of Action of Novel Therapeutics
Zhang, K.W. et al. J Am Coll Cardiol Basic Trans Science. 2019;4(3):438–48.
(A) Abnormal plasma cells overproduce k or l light chains, which misfold and aggregate into amyloid ﬁbrils. The light chain amyloid ﬁbrils
deposit in multiple end-organs causing organ dysfunction. Carﬁlzomib, daratumumab, elotuzumab, isatuximab, ixazomib, pomalidomide,
and venetoclax reduce light chain production; doxycycline inhibits formation of light chain amyloid ﬁbrils; 11-1F4, GSK2398852, and
NEOD001 remove light chain amyloid deposits from tissue. (B) Transthyretin is synthesized in hepatocytes as a homotetramer, which
dissociates into alternatively folded monomers that self-assemble to form insoluble amyloid ﬁbrils. The transthyretin amyloid ﬁbrils
deposit in multiple end-organs causing organ dysfunction. Patisiran and inotersen inhibit transthyretin synthesis by targeting transthyretin
mRNA; AG10, diﬂunisal, tafamidis, and tolcapone stabilize the transthyretin tetramer; PRX004 targets misfolded transthyretin and removes
tissue amyloid deposits; GSK2398852 removes amyloid deposits from tissue. *Drug development has been suspended or terminated.
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TRANSTHYRETIN AMYLOIDOSIS
BACKGROUND. Transthyretin is a 55,000-Dalton
protein that is synthesized primarily in the liver, and
serves as the primary serum transport protein for holo-
retinol-binding protein and a minor transport protein
for thyroxine. In plasma, <1% of transthyretin is
thyroxine-bound due to higher binding afﬁnity of
thyroxine for thyroid binding globulin and albumin
(67). Transthyretin is also synthesized in the choroid
plexus and secreted into the cerebrospinal ﬂuid (CSF),
where it serves as the primary carrier of thyroxine (68).
The transthyretin protein contains 4 identical
subunits rich in b-sheets that assemble into 2 ab di-
mers. The ab dimers contact one another at an
extended b-sheet that forms 2 funnel-shaped hor-
mone binding sites, where thyroxine binds with
negative cooperativity (68,69). Formation of trans-
thyretin amyloid ﬁbrils requires dissociation of the
tetramer into alternatively folded monomers, which
then self-assemble to form insoluble amyloid ﬁbrils
(Central Illustration, panel B) (70,71). Binding of
thyroxine stabilizes the native conformation of the
transthyretin tetramer, preventing its dissociation
into monomer units and subsequent aggregation into
amyloid ﬁbrils (72). In CSF, where transthyretin is
highly thyroxine bound, transthyretin ﬁbril formation
is generally not observed (72).
The kinetics of tetramer dissociation also explain
the predilection of mutant transthyretin for amyloid
TABLE 1 Emerging Therapeutics for Light Chain and Transthyretin Amyloidosis












Proteasome Inhibitor Carﬁlzomib IV Twice weekly for 3 weeks per 28-day cycle Yes No I/II NCT01789242
Ixazomib PO Once weekly for 3 weeks per 28-day cycle Yes No III NCT01659658
Immunomodulator Pomalidomide PO Once daily for 3 weeks per 28-day cycle Yes No I/II (terminated) NCT01807286
Anti-CD38 mAb Daratumumab SQ Once weekly (then once) per 28-day cycle Yes No III NCT03201965
Isatuximab IV Weekly (then biweekly) per 28-day cycle No No II NCT03499808
Anti-SLAMF7 Elotuzumab IV Weekly (then biweekly) per 28-day cycle Yes No II NCT03252600
BCL2 Inhibitor Venetoclax PO Daily Yes No I NCT03000660
Inhibition of amyloid
ﬁbril formation





11-1F4 IV Once weekly No No I NCT02245867




AG10 PO Twice daily No No II NCT03458130
Diﬂunisal PO Twice daily Yes No III NCT00294671
Tafamidis PO Daily No No III NCT01994889
Tolcapone PO Daily Yes No II NCT02191826
Transthyretin synthesis
inhibitor
Inotersen SQ Weekly Yes Yes III NCT01737398
Patisiran IV Once every 3 weeks Yes Yes III NCT01960348
Removal of amyloid
deposits
PRX004 IV Once every 28 days No No I NCT03336580




GSK2398852 IV Once per 11-day cycle No No II (suspended) NCT03044353
FDA ¼ U.S. Food and Drug Administration; IV ¼ intravenous; mAb ¼ monoclonal antibody; NCT ¼ National Clinical Trial; PO ¼ oral; SQ ¼ subcutaneous.
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formation. L55P and V122I-mutant transthyretin
dissociate rapidly to the monomeric amyloidogenic
intermediate and aggregate to form amyloid ﬁbrils at
a correspondingly high rate, leading to nearly 100%
disease penetrance with severe systemic disease (73).
In comparison, the V30M mutant dissociates more
slowly even than wild-type transthyretin and results
in a milder disease phenotype (polyneuropathy) with
penetrance as low as 2% (74,75). The protective T119M
variant exhibits extremely slow tetramer dissociation
and ﬁbril formation rates (73); compound heterozy-
gotes expressing both T119M and V30M transthyretin
exhibit either normal phenotype or only mild pa-
thology of late onset (76).
TRANSTHYRETIN TETRAMER STABILIZERS. Because
of the disease-modifying effect of tetramer stabiliza-
tion, transthyretin tetramer stabilizers have emerged
as a novel class of therapeutics for ATTR. Nonste-
roidal anti-inﬂammatory drugs such as diﬂunisal
were among the ﬁrst transthyretin tetramer stabi-
lizers identiﬁed, binding with higher efﬁcacy to the
central hormone-binding funnel than thyroxine (77).
Administration of diﬂunisal 250 mg twice daily in
healthy subjects slowed transthyretin aggregation
in vitro by 3-fold (78). In familial amyloid poly-
neuropathy, a phase III clinical trial of diﬂunisal
250 mg twice daily reduced the rate of progression of
neurologic impairment and preserved quality of life
over 2 years (NCT00294671) (79). Diﬂunisal was well
tolerated in an open-label study of 13 patients with
wild-type and hereditary ATTR-CA; hemoglobin,
mean arterial pressure, and glomerular ﬁltration rate
remained stable over 0.9 years of follow-up without
signiﬁcant change in cardiac structure, function, or
biomarkers (80). Larger randomized studies of diﬂu-
nisal in the ATTR-CA population are needed.
Tafamidis is a small molecule ligand in the ben-
zoxazole family that exhibits potent and selective
transthyretin binding, and lacks nonsteroidal anti-
inﬂammatory drugs activity. Tafamidis inhibits wild-
type transthyretin amyloidogenesis in a dose-
dependent manner, and also stabilizes the 2 most
clinically signiﬁcant amyloidogenic mutant homote-
tramers (V30M and V122I) with comparable potency
and efﬁcacy (81). In a phase III trial of 441 patients with
wild-type and hereditary ATTR-CA, tafamidis led to a
reduction in all-cause mortality (HR: 0.70, 95% conﬁ-
dence interval: 0.51 to 0.96) and cardiovascular-
related hospitalization (HR: 0.68, 95% conﬁdence in-
terval: 0.56 to 0.81), with a number-needed-to-treat
for the combined endpoint of all-cause mortality and
cardiovascular-related hospitalization of 7.5 (82). It
remains unknown whether tafamidis is effective in
advanced amyloid disease, as patients with New York
Heart Association (NYHA) functional class IV HF were
excluded; a small study of patients with advanced fa-
milial amyloid polyneuropathy showed no signiﬁcant
clinical improvement with tafamidis (83).
AG10 is a synthetic small molecule transthyretin
ligand whose basic protein structure was identiﬁed by
high-throughput screen, and subsequently modiﬁed
with a carboxylic acid group on the 2-ﬂuorophenyl
ring to optimize binding energetics to transthyretin
(84). AG10 binds to wild-type transthyretin with
higher afﬁnity than tafamidis or diﬂunisal; further-
more, AG10 stabilizes V122I mutant transthyretin
tetramers more effectively than tafamidis and is also
more effective in preventing V122I amyloid ﬁbril
formation (84). Both tafamidis and AG10 protect car-
diomyocytes from the proteotoxic effects of amyloi-
dogenic V122I transthyretin in vitro. AG10 is currently
in a phase II clinical trial for hereditary and wild-type
ATTR-CA (NCT03458130); a phase III trial in ATTR-CA
is projected to open in early 2019.
Tolcapone is a catechol-O-methyltransferase in-
hibitor originally approved as an adjunct to levodopa
and carbidopa for the treatment of Parkinson’s dis-
ease. It binds to the thyroxine binding pocket at the
transthyretin dimer-dimer interface with higher
afﬁnity than tafamidis, and is a stronger aggregation
inhibitor than tafamidis (85). Similar to tafamidis,
tolcapone inhibits aggregation of the V122I-
transthyretin variant although with less efﬁcacy
than wild-type transthyretin. When incubated with
human plasma, tolcapone prevents transthyretin
tetramer dissociation for wild-type and V30M trans-
thyretin with greater stabilizing activity than tafa-
midis. The unique ability of tolcapone to cross the
blood-brain barrier indicates that it may treat trans-
thyretin leptomeningeal amyloidosis, noting that the
majority of transthyretin in the CSF is thyroxine
bound. A phase II trial of tolcapone in familial amy-
loid polyneuropathy is ongoing (NCT02191826).
TRANSTHYRETIN SYNTHESIS INHIBITORS. Patisiran
is a second-generation, double-stranded small inter-
fering RNA that targets the 3’ untranslated region of
the transthyretin gene, which is conserved among
wild-type transthyretin and all reported transthyretin
mutations. Patisiran is modiﬁed with 2’-O-methyl ri-
bonucleosides for improved stability and formulated
in a lipid nanoparticle, which enables passage through
the fenestrated vascular endothelium of the liver and
targeted organ delivery (86). Endosomal endocytosis
of the lipid nanoparticle delivers patisiran to the
cytoplasm, where it triggers endogenous cellular
pathways for controlling gene expression throughRNA
Zhang et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 4 , N O . 3 , 2 0 1 9
Emerging Therapeutics for Amyloidosis J U N E 2 0 1 9 : 4 3 8 – 4 8
444
interference. Speciﬁcally, binding of patisiran to the
RNA-induced silencing complex triggers separation of
the 2 RNA strands and allows for binding of the anti-
sense strand to transthyretin mRNA. The double-
stranded RNA substrate is then cleaved and targeted
for degradation, leading to a reduction in transthyretin
protein levels (87). In animal models, patisiran
reduced transthyretin deposition and facilitated
regression of existing transthyretin deposits, with the
extent of deposit regression correlating with the level
of RNA interference–mediated knockdown (88).
In a phase III trial of patients with hereditary ATTR
with polyneuropathy, patisiran signiﬁcantly
improved neuropathy and quality of life after 18
months of therapy in the overall cohort and in the
subgroup with cardiac involvement (56%; NYHA
functional class III/IV were excluded) (86). Within the
cardiac subpopulation, patisiran led to a statistically
signiﬁcant reduction in NT-proBNP level, left ven-
tricular (LV) wall thickness, and reduced worsening in
GLS, suggestive of cardiac beneﬁt (89). Further study
of patisiran in the ATTR-CA population with the use
of clinically relevant cardiac endpoints is needed.
Inotersen is a second-generation antisense oligo-
nucleotide that targets the 3’ untranslated region of
transthyretin mRNA. Its single-stranded synthetic
oligomer contains 20 nucleotides with a modiﬁed
phosphorothioate backbone as well as 2’-O-methox-
yethyl modiﬁed ribonucleotides at each terminus,
which confer increased hybridization afﬁnity to target
RNA, increased resistance to nuclease degradation,
and reduced immunostimulatory activity (90). Sys-
temically administered inotersen distributes at high
levels to the liver, where it gains access to the intra-
cellular space via endosome activity and then moves
to the nucleus by passive diffusion and active trans-
port due to its phosphorothioate backbone (91,92).
Once bound to the target RNA through Watson-Crick
base-pairing, inotersen forms an RNA-DNA hybrid
that triggers target mRNA degradation by RNase H via
a central region of 10 2’-deoxynucleotide residues that
is recognized by the enzyme (93).
In a phase III trial of patients with hereditary ATTR
with polyneuropathy, inotersen signiﬁcantly
improved neuropathy and quality of life after 16
months of therapy in the overall cohort and in the
subgroup with cardiomyopathy (68%; NYHA func-
tional class III/IV were excluded) (94). Within the
cardiomyopathy subgroup, there was no signiﬁcant
change in LVEF, GLS, LV wall thickness, LV mass, or
lateral E/E’ ratio after 16 months of inotersen therapy,
although baseline LVEF and GLS were relatively pre-
served at 64% and 14%, respectively. Thrombocy-
topenia and, rarely, glomerulonephritis are important
safety concerns and should be monitored on a regular
basis. The safety of inotersen in patients with a prior
liver transplant for hereditary ATTR is not estab-
lished. As with patisiran, further study of inotersen in
the ATTR-CA population is needed.
CLEARANCE OF AMYLOID DEPOSITS. GSK2398852 is
an anti-serum amyloid P component (SAP) antibody
whose epitope is a glycoprotein in the pentraxin
family, a group of highly evolutionarily conserved
proteins that activate the innate immune response
upon binding to microbial ligands, apoptotic cells, and
amyloid ﬁbrils (95,96). The pentraxins have also been
found to promote amyloid deposition and disease
progression in vivo (97). In a mouse model of systemic
amyloidosis, depletion of circulating SAP followed by
administration of anti-SAP monoclonal IgG1 antibody
led to inﬁltration of macrophages and other monocytic
inﬂammatory cells into tissue amyloid deposits in a
complement-dependent fashion (98). The inﬂamma-
tory process was characterized by high-phagocyte
endocytotic activity and engulfment of amyloid de-
posits by multinucleated giant cells, culminating in
complete clearance of amyloid tissue deposits and
restoration of normal tissue architecture.
In a phase I trial, 16 subjects with systemic
amyloidosis and signiﬁcant amyloid inﬁltration of the
liver and spleen received GSK2398852 after depletion
of circulating SAP without excess toxicity (99). Pa-
tients with cardiac involvement were excluded from
this study, and there were no signiﬁcant changes in
extracellular volume of the heart, troponin T, or NT-
proBNP. However, a phase II trial of GSK2398852 in
patients with biopsy- or bone scintigraphy–proven
ATTR-CA was suspended prematurely due to an
adverse risk/beneﬁt proﬁle (NCT03044353).
PRX004 is a humanized IgG1 mAb that targets an
epitope exposed on abnormal transthyretin protein. In
preclinical models, PRX004 neutralized soluble cyto-
toxic forms of transthyretin, prevented amyloid ﬁbril
formation, and promoted clearance of organ amyloid
deposits via phagocytosis (unpublished data, courtesy
of Prothena Corporation, May 2018). A phase I dose
escalation trial is currently ongoing (NCT03336580).
FUTURE DIRECTIONS
With the emergence of multiple novel therapeutics
for AL and ATTR, there is an urgent need to deﬁne
optimal drug combinations and sequences of drug
delivery to reduce morbidity and mortality amongst
patients with AL-CA and ATTR-CA. This is particu-
larly important in the treatment of AL-CA, although
large randomized clinical trials in this population are
challenging due to low disease prevalence and poor
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performance status. Although initial therapy for AL
with a bortezomib-based regimen versus ASCT
is generally accepted, it remains unclear which regi-
mens are optimal for relapsed/refractory disease (100)
and how the novel AL therapeutics will ﬁt into the
treatment paradigm. It is likely that a multipronged
treatment approach will be optimal for both AL-CA
and ATTR-CA, and carefully executed clinical trials
are needed to determine the optimal approach.
The impact of each novel therapeutic on cardiac
biomarkers also requires clariﬁcation. NT-proBNP is an
important cardiac biomarker that correlates inversely
with prognosis in AL-CA and ATTR-CA (2,20). A para-
doxical increase in NT-proBNP has been described in
AL patients on lenalidomide despite hematologic
response and absence of cardiac symptoms, possibly
reﬂecting IMiD-induced ﬂuid retention as opposed to
direct cardiotoxicity (101,102). Additionally, a signiﬁ-
cant increase in NT-proBNP has been described in pa-
tients with advanced AL-CA on bortezomib, although
it is unclear whether this represents drug toxicity or
worsening of pre-existing cardiac disease (103). The
utility of alternate cardiac biomarkers, such as
troponin T, for assessment of drug-induced car-
diotoxicity should be explored.
Finally, validated biomarkers that track with car-
diac response to therapy are needed to rigorously
assess the cardiac efﬁcacy of emerging therapeutics
in AL and ATTR. Challenges associated with NT-
proBNP have been discussed, and also include
optimal timing of NT-proBNP assessment (104).
Whereas serial cardiac magnetic resonance imaging
studies may be useful in clinical trials, this strategy is
unlikely to be feasible in clinical practice. GLS by
echocardiography has shown value for prognosis and
diagnosis in CA, but its utility for tracking cardiac
response to therapy has yet to be explored (105,106).
Six-minute walk distance was better on tafamidis as
compared with placebo in clinical trials and corre-
lated with cardiac response to chemotherapy in AL
(82,107), and could be implemented in future clinical
trials and clinical practice as a marker of cardiac
response to therapy.
CONCLUSIONS
Cardiac amyloidosis is a restrictive cardiomyopathy
with high morbidity and mortality, and is increasingly
recognized as an underdiagnosed condition.
Although no therapies have been approved for AL- or
ATTR-CA, a number of therapeutics targeted at
neoplastic plasma cells, transthyretin protein pro-
duction, and amyloid ﬁbril formation are currently in
clinical trials. Additionally, mAbs aiming to remove
existing amyloid deposits may improve outcomes for
patients with more advanced cardiac disease. Future
efforts should deﬁne the optimal treatment para-
digms for cardiac response in AL-CA and ATTR-CA,
and identify effective clinical, imaging, and serum
biomarker strategies that reﬂect cardiac response to
therapy.
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